Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

December 11, 2025 | Pharmaphorum 

Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

- PMLiVE

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.

In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.

Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.

Read the full interview on pharmaphorum.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Demand assessment research video

Head of Business Analytics Tom Nolte and Associate Director Will Tolley discuss demand assessment research – the various techniques and when in a product’s stage of development a demand assessment…

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two…

20 questions: Round 4

As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month “What’s been the funniest thing to happen to you whilst you’ve…

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when…

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of…

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog…

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global…

TRIO OF HIRES SIGNAL PEGASUS’ NORTHERN GRIT

Growth trend continues at ‘health first, sector second’ agencyPegasus, an Ashfield company, part of UDG Healthcare plc, has announced further growth of its Pharma and Life Sciences division with the…